Imugene Receives VAXINIA ethics approval in Australia
- Imugene (IMU) receives Human Research Ethics Committee (HREC) approval to commence a phase one clinical trial of its VAXINIA drug in Australia
- The approval confirms the company has completed all necessary pre-clinical safety and efficacy testing of VAXINIA ahead of conducting human trials
- The Australian component of the trial will be conducted under the clinical trials notification (CTN) scheme
- The company will now notify the Therapeutic Goods Administration (TGA) of its HREC approval and complete local site initiation activities
- Shares in the company were up 6.25 per cent, trading at 17 cents at 11:00am AEDT
